Bihar: Gaya beneficiary gets free treatment under Ayushman Bharat scheme
Gaya (Bihar): The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), the world's largest publicly funded health assurance scheme, continues to be a lifeline for countless Indians. Offering free medical treatment worth up to Rs 5 lakh per family annually for secondary and tertiary hospital care, the scheme has emerged as a game-changer in India's healthcare landscape—especially for the poor and lower-middle-class population.
In Bihar's Gaya district, the impact of this flagship scheme is evident in the story of Lalan Chaudhary, a farmer originally from Nalanda district. Currently undergoing treatment at Magadh Medical College in Gaya, Lalan is receiving all his medical services—surgery, medicines, accommodation, and food—completely free of cost through his Ayushman Bharat card.
Speaking to IANS, Lalan Chaudhary, a beneficiary, said, 'The hips of both my legs were damaged. I've been under treatment for the last one and a half months, and it's all being done free of cost through the Ayushman card. Where would poor people like us get Rs 5 lakh for treatment? We are grateful to Prime Minister Narendra Modi. Medicines, food—everything is taken care of. This is a very good scheme.'
Chaudhary learned about the scheme when a government outreach team visited his village.
'They helped us make the Ayushman card at home itself. Now, many people in our village are benefiting from it,' he added.
Such personal accounts reflect the broader transformation in India's healthcare ecosystem over the last decade. Through a combination of digitisation, public sector engagement, and targeted welfare initiatives, the Government has brought quality healthcare within reach for millions who previously struggled with high costs and red tape.
Crucially, Ayushman Bharat addresses the needs of the "missing middle"—families who neither qualify for traditional subsidies nor can afford costly private insurance. By enabling access to timely hospitalisation and treatment without pushing families into debt, it has shifted the narrative around medical affordability.
As of May 30, 2025, more than 41 crore Ayushman cards have been issued across 33 States and Union Territories. These have enabled over 8.5 crore hospital admissions, translating into Rs 1.19 lakh crore worth of treatment covered. A robust network of nearly 32,000 empanelled hospitals, including both public and private facilities, ensures that beneficiaries like Lalan Chaudhary receive uninterrupted medical care.
The scheme's reach was further expanded in October 2024, when the Government extended coverage to all senior citizens aged 70 and above, regardless of their income status. This has particularly benefited elderly citizens in the middle-income group, offering peace of mind to families burdened by rising medical expenses.
In tandem with Ayushman Bharat, the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is revolutionising access to affordable medicines. What began with just 80 outlets in 2014 has now grown into a network of 16,469 Jan Aushadhi Kendras. These stores provide high-quality generic medicines at 50-80 per cent lower prices than their branded counterparts, all certified by WHO-GMP standards.
Together, these schemes are ushering in a silent but powerful healthcare revolution in India—bridging the gap between policy and people, and turning the right to health into a lived reality.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Weight-loss drug bulks up sales as patients upgrade dosage
Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three months. Young adults in their 30s and 40s are showing significant interest, with many upgrading to higher doses. While experts acknowledge its potential in addressing obesity, they caution about long-term efficacy, side effects, and affordability for the Indian population. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Sales of Mounjaro, Eli Lilly 's blockbuster weight-loss and diabetes drug, have touched Rs 24 crore within three months of its India launch, making it one of the most popular and fastest adopted new drugs in the country, with many people in their thirties and early forties showing sales grew 60% month on month to Rs 12.60 crore last month from Rs 7.87 crore in April, with the 5 mg injections accounting for Rs 7.53 crore—up 145% from Rs 3.08 crore in the previous month, data from industry tracker PharmaTrac showed. This indicates that patients are upgrading to higher doses after taking an initial base dose of 2.5 mg, experts doctors recommend a dose escalation to 5 mg after one month of starting the medication, depending on side effects. Mounjaro is currently available in 2.5 mg and 5 mg injections in India. Sales of 2.5 mg injections rose to Rs 5.08 crore in May from Rs 4.80 crore in April and Rs 1.42 crore in March, when it was launched, according to PharmaTrac data.'Our data indicates patients upgrading to higher dose after four weeks as well as new patients onboarding on lower dose,' said Sheetal Sapale, vice president, commercial, at endocrinologists said many people in their 30s and early 40s are reaching out to doctors to check if they could use the medication to lose weight.'There are many young people asking me if they could use the drug,' said Vyankatesh Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai. He said Indian patients are responding well to tirzepatide (Mounjaro).'Clinical trials conducted previously on Indian obese diabetes patients have shown good weight loss benefits at more than 20% as well as good sugar control,' Shivane said. 'Both semaglutide (Novo Nordisk's Wegovy) and tirzepatide have completed cardiovascular safety trials and have shown added benefits of reduction of cardiovascular events in Type 2 diabetes patients,' he drugmaker Novo Nordisk is expected to launch its blockbuster weight-loss drug Wegovy in India this year. Doctors said medications like Mounjaro and Wegovy could prove an actionable remedy in a country of 80 million obese they cautioned that it would take four to six months to assess their effect on a larger Indian population regarding actual weight loss efficacy, potential weight regain after stopping the medication, and side to Shivane, clinical trails have shown weight regain of 5-7% once the drug is stopped. 'That is where patients will need counselling in order to adopt a healthier lifestyle including healthy dietary habits and regular exercise,' he Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said, 'The molecule is good. Global studies suggest there are patients who have benefitted from it, but there are also those who have dropped out due to side effects that are mostly gastrointestinal in nature.' Commonly reported side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain. Sinha said it will take 3-4 months to tell how the drug is working on Indian patients. 'One also has to look at the affordability issue,' he added. In India, Mounjaro is priced at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial, which translates to Rs 14,000-17,500 per month, depending on the weekly dose. This means a six month treatment could cost about Rs 1 to a recent study published in leading medical journal Lancet, 70% of India's urban population is classified as obese, or overweight.'Obesity is like a pandemic in India and diabetes is very common and it is one of the useful drugs,' Anurag Lila, visiting consultant endocrinologist at Dr LH Hiranandani Hospital in Mumbai, told ET in a recent interaction.
Time of India
an hour ago
- Time of India
CM opens med college & hospital in Kandhamal; inaugurates projects worth over Rs 970cr in 2 dists
1 2 Berhampur/Bhubaneswar: A state-of-the-art medical college and hospital was inaugurated by chief minister Mohan Charan Majhi in Kandhamal district on Saturday, fulfilling a long-standing demand of locals. The 100-seat medical college and 650-bed hospital, built at a cost of over Rs 600 crore, is located at Tilakpada near Phulbani. Speaking at the inauguration ceremony, CM Majhi emphasised that the facility would provide quality healthcare services to residents of Kandhamal and neighbouring districts like Boudh, Nayagarh and Kalahandi. A govt officer said the medical college hopes to start admission from this year, subject to approval from the National Medical Commission. The 650-bed facility is an upgrade of the existing district headquarters hospital, which would now be attached to the medical college. It had 420 beds earlier. The CM highlighted his govt's commitment to healthcare, noting that the current allocation of Rs 23,635 crore for the health sector represents 8.2% of the total budget — the highest ever in the state's history. "Within the next year, we will address the doctor shortages across the state, ensuring adequate medical staff at every hospital," Majhi said. He added that around 3.50 crore people would benefit from the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), integrated with the Gopabandhu Jan Arogya Yojana, covering 29,000 private hospitals statewide. Taking aim at the previous BJD govt, Majhi criticised its failure to implement the Ayushman Yojana and alleged neglect of healthcare infrastructure over the past 24 years. During his first visit to Kandhamal as CM, Majhi also inaugurated five projects worth Rs 655 crore and laid foundation stones for five additional projects valued at Rs 94 crore. These initiatives span various sectors including water supply, education, healthcare, infrastructure and tourism. The govt plans to establish industries in every district, including Kandhamal, to boost employment opportunities. Additionally, Rs 18 crore has been allocated for developing Daringbadi as a tourist destination, with Rs 4.50 crore earmarked for the Putudi waterfall project. The inauguration ceremony was attended by health minister Mukesh Mahaling, Kandhamal MP Sukant Panigrahy, and Phulbani MLA Uma Charan Mallick, among others. Later, the CM visited Subarnapur district, where he launched 56 development projects worth Rs 323 crore. The projects included 11 completed initiatives valued at Rs 80 crore and foundation stones for 45 projects worth Rs 244 crore, encompassing road construction, irrigation facilities, bridges, healthcare infrastructure and hostels. Majhi announced plans to construct four riverbed reservoirs (ISS) on the Mahanadi at Godhaneswar, Khairmal (Birmaharajpur block), Harihar Jor (Ulunda), and Surubali (Birmaharajpur). "Subarnapur will be transformed into a golden region. Our govt has already implemented 11 out of 21 promised programmes within a year. We will continue to support the district's development without any obstacles," Majhi told a public gathering. The CM highlighted Subarnapur's rich cultural heritage, particularly noting its association with Sant Kabi Bhima Bhoi and its contributions to literature, history and traditional crafts. MP (Balangir) Sangeeta Kumari Singh Deo, who attended the event, praised the state govt's efforts in developing backward regions and acknowledged the central govt's support for infrastructure development. During the programme, Majhi also distributed work orders and assistance to beneficiaries of various welfare schemes. The initiative is part of govt's broader strategy to accelerate development in Subarnapur, with a particular focus on harnessing its river resources for regional prosperity.
Economic Times
2 hours ago
- Economic Times
One cough too many: India's TB fight isn't quite there yet
Agencies A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015. One moment Anushka (name changed) was a college student. Then her world turned upside down. It started with a persistent cough and high fever. Despite popping meds, it wouldn't go away. Tests followed and then came the news that knocked the stuffing out of her—she had a fatal form of tuberculosis (TB). With scarred lungs, she gasped for each breath. The bacteria had killed her appetite, making her frail and bony. Her skin colour changed—to dark and then grew paler. At 20, her life expectancy dwindled to a few months.'I felt weak,' she recalls, 'and preferred to be alone.'Battling extensively drug-resistant tuberculosis or XDR-TB, a form of the disease in which drugs rarely worked, Anushka's only option was to be loaded each day with scores of tablets and injections. Those came with toxic side effects. For over four years, she moved between government and private hospitals, enduring cycles of failed treatment. Relief came only when she was placed on a salvage regimen—the last option when all other interventions are exhausted—at a Médecins Sans Frontières (MSF) clinic in Govandi, Mumbai. The global humanitarian group offered Anushka a cocktail of bedaquiline, delamanid and imipenem injections, a set of very powerful meds often inaccessible to most Indians due to supply restrictions aimed at curbing drug resistance. Anushka, who has now recovered, recounted her ordeal at MSF's TB Day event in Mumbai on May 12, speaking before an audience of doctors, a quiet smile breaking through years of pain. Her journey to recovery is rare, and alien to millions in India, which reflects a public health system still failing its most vulnerable. India now accounts for more than a quarter of all TB cases reported worldwide. In 2023, the country had 26% of the global TB burden, according to the World Health Organization (WHO). Bending the curve remains difficult despite multiple national programmes. How can India improve?In 2018, when India pledged to eliminate TB by 2025, five years ahead of the set global target, the objective was clear. And progress has been made, too. Between 2015 and 2023, TB incidence (new and relapsed cases per 1 lakh population every year) fell by 18% and deaths by 24%, per is a sign in the right direction, but the number of cases are still astounding, especially when it comes to drug-resistant variants. 'India bears the highest burden of XDR-TB globally, with an estimated 110,000 new cases annually,' says Professor Anil Koul of the London School of Hygiene and Tropical Medicine. A key figure in TB drug research, Koul was part of a Johnson & Johnson team that developed bedaquiline, one of the most effective drugs against resistant TB notes that Covid-19 deepened the crisis, and underfunded research has stalled progress. Of the 27 drugs in clinical trials, none have reached Phase III. Bedaquiline remains the mainstay.A 100-day TB Elimination Challenge was launched by the government in December 2024 to amplify efforts to diagnose and treat TB at the village level, but experts aren't satisfied.'We are not on track,' says Dr Animesh Sinha, chronic care and infectious disease advisor, MSF. 'To meet the 2025 milestones of WHO's End TB strategy, India should achieve a 50% reduction in TB incidence rate and a 75% reduction in the total number of TB deaths compared with 2015.' Although numbers have fallen, the quantum has been woefully short of the target, as WHO numbers suggest.A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015.A key problem is underreporting emanating from under-diagnosis. India's notification rate (number of TB cases diagnosed and officially reported) has improved from 108 per 100,000 population in 2010 to 166 in 2023, yet many cases, especially in rural areas, go undetected.'In order to address the TB crisis, we have to find the missing cases,' says Sinha. Nonetheless, the 2025 goal helped push TB up the political agenda. Ni-kshay, a digital platform for notification and treatment monitoring, is improving reporting. But without proportionate investment in diagnostics, staffing and drug access, the pace of progress will be inconsistent. Intermittent drug shortages have been reported, and India spent just 2.1% of the National Tuberculosis Elimination Programme budget on diagnostics till 2023-24, an IndiaSpend RTI revealed. 'The 2025 target was always a stretch,' says Koul. 'But it did galvanise government machinery, leading to faster approvals for newer regimens like bedaquiline, speedier rollout across TB centres and more budgetary support, including for nutritional aid.'That said, TB continues to receive only a sliver of public health funding. But even so, he notes, there certainly is a positive trend in fighting back, considering the complexity of the disease and the socioeconomic factors shaping in an ET Morning Brief podcast in January, Dr Urvashi Singh, deputy director-general (TB), Ministry of Health and Family Welfare, said, 'The domestic budget for the national TB programme has increased over five times in the last 10 years.' India, she added, is the only high-burden country where 91% of the programme is backed by domestic detection is often the difference between quick recovery and years of suffering. Goa-based diagnostic device maker Molbio Diagnostics' Truenat, a portable molecular-testing platform, introduced in 2017, expanded diagnostic access, particularly in low-access regions. 'We supplied over 90 lakh testing kits last year and expect to provide 1.25 crore this year,' says Sriram Natarajan, CEO of Molbio, which is working with government and statelevel partners to rollout molecular testing.A Truenat test costs just Rs 640, a fraction of what imported diagnostics demand, says Natarajan. In public health, he argues, the real measure isn't price, but cost-effectiveness, especially when early detection can avert far greater globally approved diagnostics protocols remain out of reach in India. The WHO-recommended urine TBLAM test, used to diagnose TB in HIVpositive patients, is still unavailable in the country, despite successful validation studies in Mumbai in 2022. Registration barriers and lack of supply from manufacturers have led to lack of access, says Leena Menghaney, a public health lawyer based in Delhi. Supplyrelated issues could be because trials in India have yet to conclude, according to industry delays cost precious lives. Late detection risks high transmission rates and complications for patients. Dr Jennifer Furin, infectious diseases clinician, Harvard Medical School, says while Truenat is helpful and the diagnostic pipeline is robust, the outdated and slow systems for approving novel tools in India have a detrimental impact. Furin points to a critical gap: the lack of household-level prevention. Studies, including a 2023 trial published in TheLancet, show that modest nutritional support for families of TB patients can sharply reduce transmission. Another model, published in TheLancet this year, estimates that improving household nutrition alone could prevent nearly 5% of TB deaths by carrying the world's highest TB burden, regulatory reforms have been slow in India. Some gains have been made, but systemic delays continue to blunt the impact of new patients with drug-resistant TB, a new wave of treatment offers hope, but conditions apply. Regimens like a six-month, all-oral combination termed BPaLM— bedaquiline, pretomanid, linezolid and moxifloxacin—have been game-changers, replacing the gruelling 24-month regimens of daily injections and pills. 'These regimens are better tolerated and highly effective, with about 90% of people completing treatment successfully,' says Sinha. While clinicians welcome the government's push for shorter regimens, access remains limited—only 1,700 patients in India have received them, according to Dr Rupak Singla, head of the department of respiratory medicine, National Institute of Tuberculosis and Respiratory Diseases, Delhi, who spoke at the event in Mumbai. Adoption has lagged due to limited access to drug susceptibility testing for newer drugs, which is crucial for choosing an appropriate treatment strategy. The BPaLM regimen can't be given in cases where more than one organ system is involved or in patients with severe extrapulmonary disease, 'both of which are common in India,' according to Dr Alpa Dalal, head of unit, Group of TB Hospitals, Sewri, Mumbai. BPaLM should not be prescribed for patients previously treated with bedaquiline, says Dalal, unless drug susceptibility to bedaquiline and linezolid is says even in extensive pulmonary TB, where studies have shown good outcomes with BPaLM, many clinicians are cautious. In longer regimens, patients with extensive lung involvement have had higher relapse rates, compared with patients with limited disease, she explains, and that concern carries over. A study published in OUP's research platform, Oxford Academic, in March 2025 shows that bedaquiline resistance among previously treated patients can reduce the drug's warn that such resistance could undercut its effectiveness in the long term if not addressed early. But Koul says, 'Bedaquiline has galvanised TB R&D. It will remain a core component of future regimens, unless we see a dramatic rise in resistance in clinical practice.'The economics of care create barriers too. Pricing is a big hurdle. Regimens with imipenem cost thousands of rupees per day. Anushka was treated free by MSF. Else each injection alone, she said, would cost Rs 2,499. Considering the socioeconomic realities of India, perhaps this is where the government could step approach to procurement is problematic too. The country selectively joins pooled procurement platforms like the Global Drug Facility, which could reduce costs. 'India has in the past refused to participate in this, unless they had an emergency,' says policy and procurement, TB is a profoundly social disease, shaped by stigma, poverty and undernutrition. Even the best drugs won't work if care doesn't reach those who need it most. Guidelines may improve and approvals may accelerate but until the system meets people where they are, too many will be left suffered for years before she got cured. Her strength wasn't just in surviving; it was in refusing to give up. 'Even in that condition, I completed my graduation and kept chasing my dreams,' she says. India's TB response must now rise to match that grit, with urgency, equity and compassion.
